NeuraLight Selected as Finalist for 2023 SXSW Innovation Awards

Tel Aviv, Israel & Austin, Texas – February 23, 2023 – NeuraLight, the company digitizing neurological evaluation and care for Parkinson’s, Alzheimer’s, ALS, and Multiple Sclerosis, announced today that it has been selected as a finalist in the SXSW Innovation Awards.

As part of SXSW, a 10-day celebration of the convergence of tech, film, music, education, and culture in Austin, TX, the SXSW Innovation Awards recognize the most exciting creative developments in the connected world, celebrating the ever-widening variety of technological advancements, achievements and discoveries. NeuraLight is one of five finalists in the “Health & MedTech” category, selected from hundreds of companies considered for the award.

“Since moving to Austin about two years ago, I’ve been continually delighted by the artistry and passion of the people here, the culture of innovation, and the burgeoning tech scene,” said NeuraLight CEO and Co-founder Micha Breakstone, PhD. “SXSW, in many ways, exemplifies the best of all of this. I’m honored that the promise of our technology has been recognized by this group of creative trailblazers and entrepreneurs.”

The inability to chart the progression of neurodegenerative disease in patients creates a massive barrier for pharma and biotech companies developing therapies for diseases such as Parkinson’s, Alzheimer’s, ALS, and Multiple Sclerosis . Leveraging proprietary deep learning and computer vision algorithms to extract and combine oculometric measures from standard webcam or smartphone videos, NeuraLight’s platform is able to objectively evaluate patients’ neurological health status. As such, the platform supports patient selection and stratification, reduction of clinical trials’ size and length, and increased probabilities of success for disease modifying therapies.

In 2022, NeuraLight launched an application of the platform to evaluate ALS through a collaboration with a publicly-traded pharma company. The collaboration aims to demonstrate that oculometrics serve as a robust proxy for the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R).

“SXSW operates as an accelerant for creative, world-changing ideas. The ability to objectively monitor disease progression has massive implications for the advancement of neurodegenerative drug development,” said NeuraLight Chief Innovation Officer Rivka Kreitman, PhD. Prior to joining NeuraLight, Rivka spent over 26 years at Teva Pharmaceuticals where she held various roles including, Head of Global Innovative Research and Development (IR&D).“From our team of best-in-class engineers to our SAB of esteemed neurologists and Nobel laureates, we pride ourselves on having the best people dedicated to our urgent mission of revolutionizing neurological evaluation.”

The award comes on the heels of a momentous year for NeuraLight. In May 2022, the company raised a $25 million series A to support its goals of providing drug developers with a platform to more effectively measure therapeutic effect, increasing the probability of success for novel neurological therapeutics, and ushering in a new era of precision medicine for neurology.

To learn more about NeuraLight and demo the company’s technology, please visit https://neuralight.ai/.

About NeuraLight

NeuraLight is on a mission to transform the lives of billions of people impacted by neurological disorders by digitizing neurological evaluation and care. Its AI-driven platform integrates multiple digital markers to accelerate and improve drug development, monitoring, and precision care for patients with neurological disorders. The technology driving the platform includes proprietary deep learning algorithms which automatically extract a host of digital oculometric markers from facial videos captured with a standard smartphone or webcam, supporting distributed trial design. NeuraLight’s founders are repeat entrepreneurs and industry veterans (including both the co-founder of Chorus.ai and the founding CTO of Flatiron Health) leading a 39-strong team. The company is supported by renowned neurologists and two Nobel laureates as well as a stellar Scientific Advisory Board, and have raised over $30.5M to date.

Contact Information

Melissa Mowery

Account Manager

VSC for NeuraLight

neuralight@vsc.co